Crossmark

Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer’s Disease and Parkinson’s Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies

Crossref DOI link: https://doi.org/10.1007/s40263-025-01226-z

Published Online: 2025-09-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hölscher, Christian https://orcid.org/0000-0002-8159-3260
License Information

Text and Data Mining valid from 2025-09-12

Version of Record valid from 2025-09-12
More Information

Article History

Received: 22 May 2025

Accepted: 27 August 2025

First Online: 12 September 2025

Declarations

:

: C.H. is a named inventor on patents that cover GLP-1, GIP, or dual GLP-1/GIP receptor agonists as treatments for AD and PD. He is the CSO of the biotech company Kariya Pharmaceuticals Ltd.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: I am the sole author of the article and agree to be accountable for the work.

Document is current

Any future updates will be listed below